The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
a very recent meta-analysis found that diabetics on GLP1-RAs had a 5% reduced risk of neurodegenerative diseases (12% risk reduction for Alzheimer disease), interestingly the same analysis found patients on GLP1-RAs to be at 12% increased risk of developing sleep disturbances.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
a very recent meta-analysis found that diabetics on GLP1-RAs had a 5% reduced risk of neurodegenerative diseases (12% risk reduction for Alzheimer disease), interestingly the same analysis found patients on GLP1-RAs to be at 12% increased risk of developing sleep disturbances.